Biogen reports that the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) declined to institute an inter partes review of US Patent 8,399,514 (514 patent), which covers the dosing regimen of daily administration of 480 mg of Tecfidera (dimethyl fumarate), an oral treatment for multiple sclerosis (MS).

Tecfidera is an oral therapy for relapsing forms of MS, including relapsing-remitting MS, the most common form of MS. Tecfidera is currently approved in the United States, the European Union, Canada, Australia, and Switzerland.

Source: Biogen